ReviewLung Cancer (Auckland, N.Z.)2017
Bevacizumab in the treatment of NSCLC: patient selection and perspectives.
Review in Lung Cancer (Auckland, N.Z.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review.BMC cancer · 2024Pooled it
- Pooled it
- Pulmonary arterial blowout syndrome as a serious adverse event in patients with advanced lung cancer: a 12-year retrospective study.European radiology · 2026Article
- Serendipity in Neuro-Oncology: The Evolution of Chemotherapeutic Agents.International journal of molecular sciences · 2025Review
- Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression.Cancers · 2025Review
- Predictive Value of Serum VEGF Levels in Non-Small Cell Lung Cancer: A Review.Oncology research · 2025Review
- Overexpression of CXCL17 increases migration and invasion of A549 lung adenocarcinoma cells.Frontiers in pharmacology · 2024Article
- Article
- Article
- Review
- Review
- Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer.Pharmaceutics · 2023Review
- Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Current status of immunotherapy for non-small cell lung cancer.Frontiers in pharmacology · 2022Review
- The economic impact of compassionate use of medicines.BMC health services research · 2021Article
- Local Treatment of Non-small Cell Lung Cancer with a Spray-Dried Bevacizumab Formulation.AAPS PharmSciTech · 2021Article
- Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States.Pharmaceutics · 2021Review
- Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer.International journal of molecular sciences · 2021Review
- RNA-based therapies: A cog in the wheel of lung cancer defense.Molecular cancer · 2021Review
- Hypoxia-induced therapy resistance: Available hypoxia-targeting strategies and current advances in head and neck cancer.Translational oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of about 10 months. Therefore, in last decade novel targeted approaches have been developed to extend survival of these patients, including antiangiogenic treatment. Vascular endothelial growth factor (VEGF) signaling pathway plays a dominant role in stimulating angiogenesis, which is the main process promoting tumor growth and metastasis. Bevacizumab (bev; Avastin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.